

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵:C07C 49/743, 69/145, 69/24, A61K
31/12, 31/22 // A01N 35/06, 37/00

A1

(11) International Publication Number:

WO 94/15900

(43) International Publication Date:

21 July 1994 (21.07.94)

(21) International Application Number:

PCT/US93/09844

(22) International Filing Date:

14 October 1993 (14.10.93)

(30) Priority Data:

08/004,972

15 January 1993 (15.01.93)

US

(71) Applicant: LAFOR LABORATORIES LIMITED [US/US]:
4400 MacArthur Boulevard, Suite 270, Newport Beach, CA
92660 (US).(72) Inventor: FORD, Larry, C.; 19 Foxboro, Irvine, CA 92714
(US).(74) Agents: SZEKERES, Gabor, L. et al.; Klein & Szekeres, 4199
Campus Drive, Suite 700, Irvine, CA 92715 (US).(81) Designated States: AU, BB, BG, BR, BY, CA, FI, HU, JP,
KP, KR, KZ, LK, MG, MN, MW, NO, PL, RO, RU, SD,
SK, UA, UZ, European patent (AT, BE, CH, DE, DK, ES,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,
TG).




Published

With international search report.

(54) Title: ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES

(57) Abstract

Compounds having formulae (i), (ii) and (iii), where R is H, alkyl of 1 to 6 carbons, or CO-R₂ where R₂ is alkyl of 1 to 6 carbons; R₁ is H, CH₃, or (CH₂)_m-CH₃; n is an integer having the values of 2 to 10, m is an integer having the values of 1 to 6, have anti-androgen activity on secondary androgen receptor sites. The compounds are useful for treating mammals, including humans afflicted with acne, male pattern baldness, adhesions and keloids. The compounds are also effective for treating other diseases or conditions which are related to androgen receptors, such as undesirable formation of breast capsules in females after breast augmentation surgery, osteoarthritis and symptoms of Alzheimer's disease. The compounds also have inhibitory effect on the metabolism of certain microorganisms and fungi of the kind, the metabolism of which is normally known to be controllable by antiandrogen compounds.



Best Available Copy

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES
BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is in the field of new
5 chemical compositions comprising cyclo and bicyclo
alkenes which have anti-androgenic activity. The
present invention is also in the field of
pharmaceutical compositions having anti-androgenic
activity, and methods of treating mammals, including
10 humans for diseases and conditions where anti-
androgenic drugs are beneficial. Moreover, the present
invention is also in the field of controlling growth of
microorganism and fungi with anti-androgenic agents.

Brief Description of the Prior Art

15 It has been known for a long time that androgens
(male hormones) are implicated in the development of
certain diseases and undesirable conditions such as
male pattern baldness, acne, and formation of adhesions
(particularly after abdominal surgery) and keloids.
20 Moreover, androgens promote the growth of certain
microbial organisms and fungi. Androgen antagonists,
also known as anti-androgens, are compounds which block
the receptor sites activated by androgens without
bringing about an androgen like response on those
25 receptor sites. It has been recognized in the prior
art that androgen antagonists or anti-androgens can
have a beneficial effect in either curing or
alleviating the symptoms of the above-noted and related
diseases and conditions.

30 Relatively recently, and with the increasing
sophistication of the science of pharmacology, it has
been recognized that there are at least two types (sub-
types) of androgen-receptors, and that for therapeutic


purposes, it is desirable to selectively block only the so-called non-essential androgen receptors, which are implicated with the above-noted diseases or conditions (acne, male pattern baldness, keloids etc.). The present invention is directed to chemical compounds which have substantially selective antagonist effect only on these non-essential androgen receptors and are therefore useful for treating acne, male pattern baldness, adhesions and keloids, etc., without having the undesirable anti-androgen effects (such as decrease in male libido or potency) of certain other anti-androgen drugs.

United States Patent No. 4,689,345 (Kasha et al.) describes certain bicyclo alkanes which have anti-androgen effect and are useful for the treatment of acne, male pattern baldness, adhesions and keloids, and which also have inhibitory effect on the growth of certain microorganisms and fungi. The compounds described in United States Patent No. 4,689,345 include a [3.2.0]heptan-7-one moiety and an alkyl moiety. Several of the in vitro and in vivo testing and assay procedures described in United States Patent No. 4,689,345 are also applicable for testing or assaying the compounds of the present invention.


SUMMARY OF THE INVENTION

The present invention relates to new compounds having the formula (i), (ii) and (iii),

3




(i)



15

(ii)



25

(iii)

30

where R is H, alkyl of 1 to 6 carbons, or CO-R₂ where R₂ is alkyl of 1 to 6 carbons;

R₁ is H, CH₃, or (CH₂)_m-CH₃;

n is an integer having the values of 2 to 10, and

m is an integer having the values of 1 to 6.

The compounds of the invention have desirable anti-androgen activity in that the compounds are effective for treating mammals, including humans afflicted with acne, male pattern baldness, adhesions and keloids. The compounds are also effective for treating other diseases or conditions which are related to androgen receptors, such as undesirable formation of breast capsules in females after breast augmentation surgery, and symptoms of Alzheimer's disease. The compounds also have inhibitory effect on the metabolism of certain microorganisms and fungi of the kind, the metabolism of which is normally known to be controllable by anti-androgen compounds. Such microorganisms and fungi include a species of Fusarium which cause damage to agriculture, and pathogenic organisms such as Candida, Actinomyces, Norcardia, Cryptococcus, Torulopsis, Aspergillus and others. The compounds of the invention have the antagonist-like effect substantially selectively only on non-essential androgen receptors and therefore are substantially devoid of undesirable side effects (decrease of libido and male potency) of conventional anti-androgen drugs.

DETAILED DESCRIPTION OF THE INVENTION

General Embodiments

Chemical terms and names in the present description refer to and cover compounds falling within the definition that term or name as classically used in organic chemistry. The compounds of the present invention contain a double bond and therefore may have trans and cis (E and Z) isomers. In addition, the compound may contain one or more chiral centers and


therefore may exist in enantiomeric and diastereomeric forms. The scope of the present invention is intended to cover all such isomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers and
5 racemic mixtures of enantiomers (optical isomers) as well.

The novel compounds of the present invention have the structures set forth in the **SUMMARY OF THE INVENTION**, and are shown by the formulas (i), (ii) and
10 (iii).

Preferred compounds of the invention, with reference to the symbols used in formulas (i), (ii) and (iii), are those where R is H or lower alkyl, even more preferably where said lower alkyl group is OCH₃.


15 With reference to the symbol R₁, the preferred compounds of the invention are those where R₁ is H or CH₂CH₃. Further, preferred compounds of the invention are those where n is 3.

The most preferred compounds of the invention are
20 shown below, as compounds I through XII.




30 (Compound I)

6




(Compound II)

10



(Compound III)


20




30

(Compound IV)


7



10 (Compound V)




20 (Compound VI)



.. (Compound VII)


5



10

(Compound VIII)

15




20

Compound IX


25

30



10

Compound X




20

Compound XI

25

30



Compound XII

Synthetic Procedures for Obtaining the Compounds in

15 Accordance with the Invention

Generally speaking, the compounds of the invention which correspond to formula (i) are obtained as one of the products of the reaction between 3-(acetyloxy)-cyclohexanone and a triphenylphosphonium salt derived from triphenyl phosphine and a bromo or (chloro) alkoxy alkane.

Compounds of the invention which correspond to formula (ii) are obtained as one of the products of the reaction between 3-chlorocyclopentanone and a Grignard reagent derived from compounds having the general structure $X-CH_2CH=CH(CH_2)_{n-2}CH(OR)R_1$ where X is halogen and the other symbols have the definition provided in connection with formula (ii).

Compounds of the invention which correspond to formula (iii) are obtained in accordance with Reaction Scheme 1. As it can be seen in the Reaction Scheme, spiro[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane-2-one (Compound XIII, a monoketal "derived" from

bicyclo[3.3.0]octan-7,2'-dione) is reacted with a Grignard reagent of Formula 2 where the symbols n and R are defined as in connection with formula (iii), and where "TBDMS" means t-butyldimethylsilyl. The

5 resulting tertiary alcohol of Formula 3 is thereafter dehydrated by reaction with thionyl chloride in pyridine to provide a mixture of olefins of Formula 4. Deprotection in the form of removal of the ketal forming "ethylene glycol" moiety and of the t-

10 butyldimethylsilyl group, by treatment with aqueous hydrogen fluoride provides the olefin mixture of Formula 5. Separation of this olefin mixture by chromatography yields compounds of formula (iii), where the R group, as defined in connection with (iii), is H.


15 Acylated and alkylated derivatives, of the compounds where R is H can be obtained by conventional means, such as acylation with an acyl chloride, acyl anhydride, or alkylation with an alkyl halide.

20

25

30

12




Reaction Scheme 1

The starting material for Reaction Scheme 1, namely spiro[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane-2-one (Compound XIII) can be obtained in accordance with the sequence of reactions set forth in Reaction Scheme 2. In accordance with this scheme, ethyl 3-oxotricyclo[3.3.0.0^{2,8}]octan-2-ylcarboxylate (Compound XIV) is reacted with sulfuric acid in acetic acid to yield exo-6-acetobicyclo[3.3.0]octan-3-one (Compound XV). For Compound XIV see the published literature procedure of Callant et al. Tetrahedron 37, 2079-84 (1981), which is incorporated herein by reference. The ketone function of Compound XV is thereafter protected by forming a ketal with ethylene glycol, yielding Compound XVI. The acetyl function of Compound XVI is removed by treatment with base, and the resulting secondary alcohol (Compound XVII) is oxidized with pyridinium dichromate (PDC) to yield Compound XIII. The oxidation with pyridinium dichromate is performed in accordance with the procedure of Corey et al., Tet. Lett. , 399-402 (1979), which is incorporated herein by reference.

25


30

14



The preparation of the reagents which introduce the side chains into the compounds of the invention, namely the bromo or chloro alkoxy alkanes for the synthesis of compounds of formula (i), the compounds of the general structure $X-CH_2CH=CH(CH_2)_{n-2}CH(OR)R_1$ for the synthesis of compounds of formula (ii), and the reagents of Formula 2. (See Reaction Scheme 1), can be prepared in accordance with synthetic methods disclosed in the literature and are available within the skill of the ordinary practicing synthetic organic chemist. By way of illustration, the following examples are provided.

1-Bromo-5-methoxyheptane (Compound XX) is a reagent used for preparing preferred compounds I and II. Compound XX is prepared in accordance with Reaction Scheme 3, starting from commercially available 2-methyl-1,3-cyclohexanedione. Thus, with reference to Reaction Scheme 3, 2-methyl-1,3-cyclohexanedione is reacted with base ($Ba(OH)_2$) to yield 5-oxoheptanoic acid (Compound XXI). The oxo function of 5-oxoheptanoic acid (Compound XXI) is thereafter reduced, and the resulting hydroxy group, as well as the carboxylate function, are methylated to give methyl 5-methoxyheptanoate (Compound XXII). The carboxylate group of the latter is reduced ($LiAlH_4$) to give 5-methoxy-1-heptanol (Compound XXIII), which is thereafter reacted with carbontetrabromide to yield 1-bromo-5-methoxyheptane (Compound XX).



1-bromo-5-methoxypentane (Compound XXX) is a reagent utilized for making preferred compounds III and IV. Compound XXX can be prepared from 5-bromo-1-pentanol (Compound XXXI). 5-bromo-1-pentanol (Compound XXXI) in turn, is obtained by hydrolysis of 5-bromopentanol-1-acetate (Compound XXXII), which itself is obtained from tetrahydropyran in accordance with the procedure described in United States Patent No. 2,922,788 (Parcel), the specification of which is incorporated herein by reference.

1-Chloro-5-methoxy-2-heptene (Compound XL, boiling point 93-95° C) is a reagent utilized for the preparation of preferred compounds V and VI. Compound XL can be prepared within the skill of the practicing organic chemist from commercially available 5-hydroxy-1,4-heptadiene. The latter is methylated, for example with methyl bromide in the presence of strong base (sodium metal), and thereafter hydrogen chloride is added to saturate one double bond. Compound XL is the minor product of this addition, which is nevertheless isolable by distillation, or by other conventional techniques.

1-Chloro-5-methoxy-2-pentene (Compound L) is a reagent utilized for the preparation of preferred compounds VII and VIII. Compound L can be obtained from commercially available 5-hydroxy-1-pentyne by first reacting the latter with methylbromide in the presence of strong base (sodium metal), and thereafter adding one molecule of hydrogen chloride gas to the triple bond. The addition is accompanied by double bond migration, and Compound L is the minor but nevertheless isolable product (boiling point 82-84 °C.)

The reagents of Formula 2 (see Reaction Scheme 1)

are utilized in the preparation of compounds corresponding to formula (iii), and such reagents having a 5-carbon chain and a 7-carbon chain, respectively, are used for the synthesis of preferred compounds IX, X, XI and XII. These reagents can be obtained, within the skill of the practicing organic chemist, by reacting the appropriate 1-halogeno-hydroxy alkane with t-butyldimethylsilyl chloride. For example 1-(t-butyl,dimethylsilyloxy)-5-bromopentane or the corresponding 5-chloro compound (reagents used in the synthesis of preferred compounds IX and X) is made by reacting the corresponding primary alcohol with t-butyldimethylsilyl chloride.

BIOLOGICAL TEST RESULTS, CLINICAL TEST RESULTS

The beneficial anti-androgen activity of the compounds of the present invention can be confirmed by a number of tests, which are described in detail in United States Patent No. 4,689,345. The specification of United States Patent No. 4,689,345 is hereby expressly incorporated by reference. The results of tests and clinical data obtained with the novel compounds of the present invention are described below, together with a brief description of the nature of the disease, condition which is treated by the compound, and of the test in which the compounds have been applied.

Acne Vulgaris

Androgenic hormones are known to be causal in instigating the chain of effects which result in acne vulgaris as well as many other types of acne. The androgens stimulate the sebaceous glands to produce sebum which is then acted upon by bacteria ubiquitous in the population to produce free fatty acids which

then act as mediators of inflammation. Several therapeutic modalities may be used at each of the above steps in the "acne cascade". For example, antibiotics, both topical and/or systemic can be used to decrease the amount of bacteria on the skin, desquamating agents such as benzoyl peroxide can be used to decrease oil content of the skin, or vitamin A analogs such as Retin A (Ortho) or Acutane (Hoffman LaRoche) can be used to decrease oil synthesis. A disadvantage of these prior art treatments, however, is that they work by poisoning fatty acid metabolism which can have very severe side effects on the skin, liver, and especially on a developing fetus.

In a test wherein inhibition of the binding of androgens to nuclear receptors is measured, sebaceous gland preparations were obtained from patients who underwent excision of acne lesions for cosmetic reasons, Compound II was found to block between 58 - 86 percent of the androgen receptors found in these isolated sebaceous gland preparations from patients with severe acne vulgaris.

Clinical Acne Vulgaris

In fifteen volunteers, ages 22 - 27, with a diagnosed history of severe acne vulgaris, all of whom had been seen by dermatologists, applied 0.5 mg of Compound I (dissolved in ethyl alcohol) twice a day to affected areas. In all of this study population, new acne lesions did not erupt after the second week of therapy and clearing with remission occurred after the third week of therapy.

Androgenic Alopecia

The loss or thinning of frontal hair in men has been reported to be universal with advancing age. In

this genetically determined condition, the role of androgen metabolism has been more clearly established in male patients undergoing hair transplantations procedures. Research by the present inventor has
5 demonstrated highly significant differences between the androgen receptor protein between balding, frontal tissues and hair bearing, occipital tissues.

Frontal (balding) tissues were examined for the effects of the subject antiandrogens.

10 **Clinical Androgenic Alopecia**

Compound I was applied to the balding (frontal) regions of ten (10) volunteers, ages 27 - 38, twice a day, 0.5 mg per application. The compound was applied in alcohol solution. In this population, as measured
15 by using filter paper to occlude the drain, the hair loss was 75 - 177 hair per day. After six weeks of the above regimen, the loss was less than seven (7) per day. Terminal hair was visibly regrowing after ten weeks of applications and there were no side effects.

20 **Androgenic Alopecia**

In tissues samples obtained from balding frontal tissues of patients undergoing hair transplant operation, the following percent of Excess (non-essential) frontal receptor was blocked by the
25 exemplary compounds of this invention.

Compound I Compound III Compound VII Compound XII

CL

*1:100

*1:100

*1:100

*1:100

*1:1000

5 Patient

1	88	80	71	49	68
2	95	81	69	46	20
3	90	80	72	50	69
4	95	82	68	55	75
10 5	95	84	59	52	72

*ratio of dihydro testosterone (DHT) to "antiandrogen" test compound.

CL = CYOCTOLTM

15 Biological Assays for Activity of Compounds (Nuclear receptors)

20 The nuclear receptors of androgens are very temperature labile. The tissues are chilled immediately to 0°C unless being used as tissue culture explants, and then are immediately minced and placed in an appropriate tissue culture media. Radio labelled steriods are obtained from either New England Nuclear or Amersham. All other chemicals were of reagent grade obtained from commercial sources.

25 Nuclear receptors containing suspensions are added to ³H or ¹⁴C radiolabelled dihydrotestosterone (or other sex steriod) in order to achieve final concentrations of radiolabelled steriod of at least 2.0, 1.0, 0.6, 0.3, and 0.15 nM. It should be observed that other concentrations of steriods are some times used in various experiments. Also, when indicated, exogenous sex steriods are removed by prior treatment with 0.5% Dextran T-70-gelatin activated charcoal.

30 The radiolabelled steriod and the receptor

preparations are reacted for an appropriate interval (1 - 24 hours), unbound radiolabelled steroid removed and an aliquot counted in a scintillation counter. Non-specific binding is determined at each concentration of radiolabeled steroid by adding a 200 fold excess of unlabelled steroid.

Specific receptor binding is then determined by the methods of Scatchard with the modification suggested by McGuire.

Anti androgenic activity is determined by adding the test compound at various final ratios to the radio labelled steroid, usually 0:1 to 10^4 :1, respectively.

Tissue Culture Assays for Anti androgen Activity

Tissue culture lines established either from surgical explants or commercial sources are plated as the final "transfer" prior to experimentation into at least three 75 cm³ flasks. The cells are removed and placed after counting into 36 well tissue culture tray, one 36 well tray for each concentration of steroid to be assayed. Non specific binding is determined by adding a 200 fold excess of unlabelled steroid. Anti androgen activity is determined by adding test compound to steroid at ratios of 0:1 to 10^4 :1, respectively. After incubation, radioactivity is determined by a scintillation counter.

Specific binding is determined as in the previous example. Further information relating to steroid binding assays can be obtained from the specification of United States Patent No. 4,689,345 (incorporated herein by reference) and from the publications Scatchard, G. The Attraction of protein for small molecules and Ions Ann. N.Y. Acad. Sci. 51: 660-672, 1949; Chamness, G. C. and McGuire, W.L., Scatchard,

plots: Common Errors in Correction and Interpretation
Steroids 26(4) : 538-542, 1975.

Anti-Fungal Activities

5 The inventor's earlier research, as well as that
of several other investigators, have established the
presence of sex steroid receptors in most fungal
organisms.

Furthermore, the drugs that are presently
clinically available against fungi, such as
10 Amphotericin B, have very significant renal toxicities,
as well as other organ side effects. Therefore, the
compounds of the present invention which are capable of
controlling fungal growth are valuable either alone or
in combination with conventional antifungal compounds.

15 Anti-Fungal Clinical Studies

In 7 volunteers with chronic (≥ 7 infections/yr)
Candidia vaginitis, Compound I was absorbed on to
clotrimazole (100 mg/suppository) for intra-vaginal
use. All seven of these volunteers experienced culture
20 and clinical cures compared to only 2/7 with culture
and clinical cures with the same medication and regimen
prior to entry to the study.

Anti-Fungal Testing (Cont)

It was found that production of mycotoxins by the
25 Fusarium species decreased by 79% as a result of
addition of $1 \times 10^{-3}M$ of Compound II to the test media.

Contamination of grains with mycotoxins is the
most significant cause of spoilage and wastage of
grains world wide. These organisms, in particular the
30 Fusarium species have significant levels of sex steroid
binding proteins. Furthermore, some of these
mycotoxins such as zearalone zearalenol are also
estrogenic, thus further emphasizing the role of sex

steriods in these fungi.

In vitro Anti-Fungal Testing

The minimal fungicidal concentration (MFC) of Amphotericin B against Cryptococcus neoformans and Coccidioides immitis were reduced by more than two serial dilution tubes by the addition of $1 \times 10^{-8}M$ of Compound II. Similar reductions of MFC were seen with similar concentrations of compounds also against Cryptococcus neoformans and Coccidioides immitis.

Also, specific DHT binding was reduced at concentrations of DHT to anti androgen of 1:100 by 57 to 93% in isolates of the above organisms.

Clinical Skin Testing (Anti-wrinkling effect)

Ten volunteer, patients applied 0.1 mg/application of Compound I twice a day, to the lateral palpebral fissures. Prior to and at the termination of this ninety day study, dental impression polymer, after activation, was gently pressed against the study site. Scanning electron microscopy was performed and in all patients the "pore" size was decreased significantly and the surface area of the wrinkles were also reduced in all measurable areas by more than 40%.

Ten volunteer patients, aged 30 - 55 applied Compound I at 0.5 mg/application, twice a day to the suprapubic region. This area was selected because, in this population this skin area was not damaged by solar ultraviolet radiation. Also, this area is very active in androgen metabolism and has a high incidence of keloid formation. Prior to and at the termination of this study, patients underwent punch biopsies of this area. The tissues were stored at $-70^{\circ}C$ until analyzed for both elastin and collagen. In all the study patients, the amount of collagen was not effected, but

of great significance was the de novo formation (synthesis) of elastin. As elastin synthesis normally ceases by age twenty-five, the present data demonstrate excellent clinical response to compounds of the invention.

Alzheimer's Disease (Clinical Efficacy)

The glial cell is thought to have many of the functions within the central nervous system (CNS) at the fibroblast in other parts of the body.

Furthermore, the glial cell has been demonstrated in the inventor's research to have androgen receptors in the nucleus.

While the causes as well as much of the pathophysiology of Alzheimer's Disease is unknown, atrophy of the cerebral cortex and "scarring" of the glial cell has been established.

Five patient with stage I Alzheimer's disease were given orally 0.5 mg of Compound I twice a day. It was observed by the volunteer's families that by the second week of therapy, recognition, mobility, cognitive abilities, and physical activity improved in these patients and the patients regressed after the three month study period.

Treatment of Osteoarthritis

Twelve patients, ages 55-78 with a diagnosis of osteoarthritis were treated with one mg. of compound 1 once daily. The test material was applied to the skin surrounding either the wrists, knees, or hands. In the case of the wrist or knee application, the skin was occluded with a polymer, elastic dressing or in the case of the hands, occlusive polymer gloves. The skin was occluded for one hour then the occlusive dressings were removed. At the fourth to seventh day, all

patients noted markedly decreased pain and by the fourteenth day, all patients had increased mobility. Additionally, all patients were able to reduce their dosage of non-steroidal anti-inflammatory drugs.

5 **Inhibition of Breast Capsule Formation**

Breast capsules formation following surgery for mammary augmentation for either reconstructive or cosmetic indications is the most significant and potentially disfiguring complication of these
10 surgeries. Such capsules form in 5 - 90% of the patients. In the inventor's earlier research, this problem was viewed as a subdermal keloid because of the histopathological appearance and very high
15 concentrations of non-essential androgen receptor proteins in the capsule tissue. For the present tests surgical explants were obtained from patients
undergoing surgical excision of the breast capsules for appropriate surgical indications. These explants were established in tissue culture.

20 **Breast Capsules (Clinical Efficacy)**

In 5 volunteers who had previously undergone mammary augmentation and subsequently developed deforming capsules formation bilaterally, **Compound I** was applied topically in alcohol solution at 0.1%
25 concentration, twice a daily. In all patients, at the end of thirty days, the capsules decreased in mass so much that gentle pressure allowed their disruption. The patients continued to apply the compound for an additional 60 days with no further recapsulation.

30 **Breast Capsules Fibroblasts - Tissue Culture**

Percent of excess (non-essential) androgen receptors blocked.

Patient	Compound #I	Compound #IV	Compound #VIII	Compound #IX	CL 1:1000
	1:100	1:100	1:100	1:100	
1	86	76	69	46	77
2	90	79	60	49	64
3	95	81	58	44	78
4	96	82	59	44	81
5	89	70	62	51	61

CL = CYOCTOLTM Whole Cells

Percent of excess (non-essential) androgen
receptor blocked

Patient #	Compound #I	Compound #IV	Compound #VIII	Compound #IX	CL 1:1000
	1:100	1:100	1:100	1:100	
1	86	72	62	42	66
2	89	73	60	46	71
3	79	64	57	49	55
4	87	76	49	51	73
5	78	49	53	50	48

Biological Assays - Keloids and Capsules

CL = CYOCTOLTM

Keloids are among the most common disorders of healing of wounds and among the earliest described conditions of the skin being described in the Smith papyrus dating to 2500 B.C. The role of the sex hormones in keloids has been observed by several investigations, but it was the present inventor's research that identified the markedly elevated levels of androgen receptors in these tissues.

The effects of the compounds of the invention were assayed in surgical explants of keloids as well as in homogenates from whole keloid tissues. The surgical explants were obtained aseptically from patients

undergoing surgical removal of their keloid(s). The explants were established in tissue according to standard methods.

The compounds were assigned at a final combination of DHT to compound of 1:4, 1:10, 1:100 1:1000, 1:10,000, respectively.

The compounds blocked the DHT receptor protein only in the non essential receptor, and not in the essential receptor even in doses of 10^4 to one.

In the whole tissue preparations, very similar results were obtained.

Keloids

Percent of excess (non-essential) androgen receptor blocked.

	Compound #I		Compound #II		Compound #III		Compound #IX	
	Patient #	1:100	1:100	1:100	1:100	1:100	CL 1:1000	1:1000
15	1	98	88	72	33	80		
	2	95	88	66	39	83		
20	3	98	81	68	46	79		
	4	90	74	69	35	68		
	5	98	82	72	41	81		

CL = CYOCTOLTM

Keloids (Fibroblasts) Percent of excess (non-essential) androgen receptor blocked.

	Compound #I		Compound #II		Compound #V		Compound #X	
	Patient #	1:100	1:100	1:100	1:100	1:100	CL 1:1000	1:1000
30	1	95	87	79	46	77		
	2	95	85	70	51	72		
	3	95	80	69	49	68		
	4	97	82	70	51	84		
	5	98	83	72	39	78		

CL = CYOCTOLTM

Clinical Keloids

Compound I was injected intralesionally into volunteers with keloids at a dose of 0.2 mg/cm³ of estimated keloid volume. In 3/5 patients, the keloid regressed completely after the second dose given 1 week after the first dose. The remaining (2/5) patients' keloids completely regressed after the third intralesional injection.

Compound I was suspended in base as applied twice a day to the keloids of 5 volunteers at a concentration of 0.01%. A fifty percent decrease in the keloids were seen at 40-60 days and regression to a normal cistothrix at 150 - 180 days. This type of application was significantly slower than the intralesional injections.

Biological Assays of Adhesions

The most common cause of involuntary sterility in human females is the sequelae of chronic pelvic inflammatory disease. Furthermore, the most common and significant cause of long term surgical complications is also dense adhesions which in the above examples have a very similar histopathological appearance.

These dense adhesions are not unlike the dense banks of collagens and fibroblasts seen in the histopathological appearance of keloid or hypertrophic scar tissues. Furthermore, as with keloids, these dense adhesions have elevated levels of androgen receptor proteins, with "normal" levels of both estrogen and progesterone receptor.

The effects of these anti-androgen compounds of the present invention on these abnormal tissues were assayed both in vivo and in vitro.

The tubo-ovarian abcess model of Hammill et al. A Rat Model of Unilateral Utero-Tubo-Ovarian Abscess, REVIEWS OF INFECTIOUS DISEASES, Vol. 6, Supplement 1-5, March-April 1984 was used to access the effects of these compounds on adhesion formation in the rat. Briefly, this model uses anaerobic and aerobic bacteria to form an abcess which stimulates very closely the human clinical stimulation.

The rats were given Primaxin (MSD) intra veinously and the compound of the invention intraperitoneally. Animals were sacrificed at twelve (12) weeks and the resultant scarring scored according to the Gainesville method of grading the stage of pelvic inflammatory disease. It should be observed that these compounds do not have antibacterial activity at these doses and therefore the Primaxin (MSD) was essential to prevent the animals dying of septic shock. Furthermore, it should be observed that Primaxin (MSD) is FDA approved for this clinical indication.

As is evident, the compounds of the invention were highly effective in preventing adhesions in this tubo-ovarian abcess model.

Adhesions Rat Model

Grade of Adhesions Primaxin (MSD) Primixin + Compound I

IV, n = 8	O, n = 8
III, n = 2	I, n = 2

Surgical Adhesions in Humans.

Clinically significant dense adhesions were obtained from patients undergoing gynecological surgery with the diagnosis of a prior history of pelvic inflammatory disease for gynecological indications. These surgical explants were cultured according to the methods above.

As is very evident, all the test compounds worked at ratios which could be readily and easily achieved clinically.

5 Surgical explants of clinically dense intra abdominal adhesions were obtained from general surgical patients with the diagnosis of complications secondary to these adhesions.

Percent of excess (non-essential) androgen reactor blocked

10		Compound	Compound	Compound	Compound	
		#1	#II	#VI	#IX	
	Patient	1:100	1:100	1:100	1:100	Cl 1:1000
	1	88	72	58	37	70
	2	86	74	57	41	70
15	3	88	79	59	46	69
	4	91	75	62	49	74
	5	78	69	60	35	51

CL = CYOCTOLTM

Adhesions (fibroblasts)

20 Percent of excess (non-essential) androgen receptor blocked

		Compound	Compound	Compound	Compound		
		#1	#II	#VI	#IX		
Patient		1:100	1:100	1:100	1:100	Cl	1:1000
25	1	77	70	69	56		43
	2	89	75	41	42		66
	3	87	80	60	41		59
	4	85	79	55	55		86
	5	79	80	59	53		42

30 CL = CYOCTOLTM

FORMULATIONS, METHODS OF ADMINISTRATION

The above-described clinical tests have provided examples for administration of the compounds of the

present invention. Generally speaking, depending on the disease or condition to be treated or alleviated, the compounds of the invention may be delivered topically or systemically, in such pharmaceutical compositions which are commonly used in the art for the desired delivery. Specifically, shampoos, ointments and sustained release transdermal compositions can be used for topical delivery of the compounds of the invention. Shampoos are particularly advantageous for treatment of male pattern baldness. Systemic delivery of the compounds of the invention can be through oral dosage units, such as tablets, capsules and liquid oral dosage units. Sublingual administration and administration through rectal suppositories is also feasible, as well as administration by injection. Control of fermentation processes with the compounds of the invention may be affected by adding the applicable compound to the fermentation process in a suitable solvent, such as ethanol.

Generally speaking treatment of any disease or condition in mammals, including human patients, will be effected by administration of the therapeutically effective dose of one or more compounds in accordance with the instant invention. A therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards its expansion. In certain instances, the drug potentially could be used in a prophylactic manner to prevent onset of a particular condition. A given therapeutic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given

therapeutic concentration will be best determined at the time and place through routine experimentation. However, it is anticipated that for a normal adult a dosage of 0.0001 to about 40 mg per oral dosage unit form of the active compound will be used for systemic delivery, and preferably the oral dosage will be from about 0.01 mg to about 2 mg per oral dosage unit form. For topical (transdermal) applications it is anticipated that the pharmaceutical composition (such as ointment, cream, solution etc.) will contain a concentration of 0.001 to 5 % by weight of the active compound of the invention. A more preferred range of concentration is from about 0.05 to about 3 % by weight.

For still further descriptions of routes and modes of administration, and methods of treatment, reference is made to the specification of United States Patent No. 4,689,345 (incorporated herein by reference).

SPECIFIC EXAMPLES

20 5-Oxoheptanoic acid (Compound XXI)

A modification of the procedure of Ijima et al. Chem. Pharm. Bull. 19, 1053 - 5 (1971) was used. A solution of 2-methyl-1,3-cyclohexanedione (40 g, 0.317 mole, Aldrich) and Ba(OH)₂·8H₂O (360 g) in water (840 mL) was heated at reflux for 48 h. After standing overnight at room temperature and cooling to 0°C, the precipitated barium hydroxide was removed by suction filtration. CO₂ gas (generated from Dry Ice) was bubbled through the filtrate to precipitate any remaining barium hydroxide as barium carbonate. The precipitate was removed by suction filtration, and water was removed in vacuum until crystallization started. The resulting mixture was acidified to pH 1

(conc. HCl) and extracted with OEt₂ (3 x 300 mL). The extract was dried (Na₂SO₄) and stripped of solvent in vacuum giving 5-oxoheptanoic acid (Compound XXI) as a white solid (43.3-45.1 g, 95-99%, lit.¹¹² 69%): mp 48-49.5°C (lit.¹⁸² 50°C); IR (KBr pellet) cm⁻¹ 3000 (very br), 1725, 1710, 1690, 1460, 1435, 1420, 1380, 1340, 1280, 1210, 1120, 1085, 985, 910, 770, 685; ¹H NMR (200 MHz, CDCl₃) δ 10.2 (br, 1H), 2.51 (t, 7.1 Hz, 2H), 2.43 (q, 7.3 Hz, 2H), 2.40 (t, 7.1 Hz, 2H), 1.91 (rough pentet, 2H), 1.06 (t, 7.3 Hz, 3H); ¹³C NMR (22.5 MHz, CDCl₃) δ 211.5, 178.6, 41.0, 36.0, 33.1, 18.7, 7.8; mass spectrum (16 eV) m/e (% base) 144 (M⁺, 4.1), 126 (61.3), 115 (88.8), 98 (40.0), 87 (40.1), 70 (21.3), 57 (100); TLC (OEt₂, I₂) R_f = 0.37.

15 Methyl 5-methoxyheptanoate (Compound XXII)

5-Oxoheptanoic acid (Compound XXI) was reduced using a modification of the procedure reported by Ijima et al. supra. NaBH₄ (10 g, 0.26 mole) was added in portions to a stirred solution of 5-oxoheptanoic acid (Compound XXI, 28.8 g, 0.20 mole) in 10% aqueous NaOH (200 mL, 0.50 mole) so that the temperature never exceeded 55°C. The reaction was stirred at 40°C for 12 h and then cooled to 0°C. Concentrated HCl was added slowly (vigorous reaction at first) to pH 1. The stirred reaction was allowed to come to room temperature and then heated briefly to 90°C. After slow cooling, the resulting 2-phase mixture was extracted with OEt₂ (4 x 250 mL). The extract was dried (Na₂SO₄). Removal of the OEt₂ gave 30.3-31.5 g of a yellowish oil containing a small amount of suspended solid. The mixture, consisting mainly of 5-hydroxyheptanoic acid (57) and 6-ethyl-tetrahydro-2H-pyran-2-one (56), was used without further

purification. (The ratio of acid to lactone is usually about 2:3 as seen by integration of the methine protons of each molecule. The methine proton resonance for the acid is centered at 3.6 ppm and the methine of the
5 lactone is at 4.2 ppm. When the mixture is distilled, water is collected and then pure lactone, bp 55-7°C (0.2 mm), (lit.¹¹² bp 102-10°C (5 mm)); IR matches literature;¹¹² ¹H NMR (60 MHz, CDCl₃) δ 3.95-4.45 (m, 1H), 2.2-2.9

10 (m, 2H), 1.3-2.2 (complex, 6H), 1.0 (t, 7 Hz, 3H).)

The mixture was combined with absolute MeOH (300 mL), HC(OMe)₃ (400 mL), and H₂SO₄ (10 mL), stirred 2-3 days at room temperature, poured into sat. aqueous NaHCO₃ (2 L), and extracted with OEt₂ (3 x 300 mL).
15 The extract was washed (250 mL sat. NaHCO₃; 100 mL brine) and dried (Na₂SO₄). Removal of the solvent gave a slightly yellow oil (32-46 g). Distillation gave a forerun, bp 35°C (52 mm) and then methyl 5-methoxyheptanoate (Compound XXII, 27.2-30.7 g, 78-88%)
20 as a colorless oil: bp 117°C (36 mm); IR (film) cm⁻¹ 2960, 2940, 2880, 2825, 1745, 1465, 1440, 1380, 1370, 1250, 1200, 1170, 1130, 1095, 1030, 1010, 990, 925, 885, 830; ¹H NMR (200 MHz, CDCl₃) δ 3.67 (s, 3H), 3.32 (s, 3H), 3.10 (rough pentet, 1H), 2.33 (t, 7.4 Hz, 2H),
25 1.4-1.85 (complex, 6H), 0.89 (t, 7.4 Hz, 3H); ¹³C NMR (22.5 MHz, CDCl₃) δ 174.1, 81.7, 56.4, 51.5, 34.2, 32.4, 25.8, 20.9, 9.3; mass spectrum (70 eV) m/e (% base) 174 (M⁺, not observed), 159 (1.4), 145 (25.2), 113 (38.6), 111 (10.9), 83 (13.1), 74 (12.7), 73 (100),
30 71 (93.3); high resolution mass spectrum (70 eV) m/e 159.1035 (M⁺ - CH₃., calculated 159.10215 for C₈H₁₅O₃), 145.0852 (M⁺ - CH₃CH₂., calculated 145.0865 for C₇H₁₃O₃). TLC (OEt₂, vanillin dip) R_f = 0.60.

5-Methoxy-1-heptanol (Compound XXIII).

A stirred suspension of LiAlH_4 (15.2 g, 0.40 mole) in dry OEt_2 (700 mL) was cooled to 0°C . Methyl 5-methoxyheptanoate (Compound XXII, 34.8 g, 0.20 mole) in dry OEt_2 (100 mL) was added dropwise over 1/2 h. The reaction was allowed to slowly warm to room temperature and stirred for an additional 12 h. The excess hydride was destroyed by dropwise addition of sat. aqueous Na_2SO_4 (extremely vigorous reaction) to the rapidly stirred reaction mixture until the gray color was completely destroyed and only a snow white precipitate remained (further addition of sat. Na_2SO_4 increased the water content of the product and necessitated drying before the next reaction). The precipitate was filtered and washed with dry OEt_2 (5 x 300 mL). Removal of the ether gave 5-methoxy-1-heptanol (Compound XXIII, 29.2 g, 100%) as a colorless oil, sufficiently pure for further reactions: IR (film) cm^{-1} 3390, 2970, 2945, 2875, 2830, 1465, 1440, 1380, 1200, 1170, 1135, 1094, 1060, 1040, 918; ^1H NMR (200 MHz, CDCl_3) δ 3.66 (m, 2H), 3.33 (s, 3H), 3.10 (rough pentet, 1H), 1.74 (s, 1H), 1.3-1.7 (complex, 8H), 0.89 (t, 7.4 Hz, 3H); ^{13}C NMR (22.5 MHz, CDCl_3) δ 82.2, 62.4, 56.4, 32.8, 32.8, 25.8, 21.6, 9.4; high resolution mass spectrum (70 eV) m/e 146 (M^+ , not observed), 117.0918 ($\text{M}^+ - \text{CH}_3\text{CH}_2\cdot$, calculated 117.0916 for $\text{C}_6\text{H}_{13}\text{O}_2$); TLC (OEt_2 , vanillin dip) R_f = 0.30.

1-Bromo-5-methoxyheptane (Compound XX)

A solution of 5-methoxy-1-heptanol (Compound XXIII, 27.7 g, 0.19 mole), CBr_4 (116.7 g, 0.38 mole), pyridine (15.4 mL, 0.19 mole), and dry OEt_2 (750 mL) was stirred mechanically under an inert atmosphere and cooled to 0°C . PBr_3 (105 g, 0.40 mole) dissolved in

OEt₂ (500 mL) was added dropwise over 5 h. Stirring was continued at 0°C for 4 h and then at room temperature overnight. The solvent was removed in vacuum at 0°C giving a pinkish solid which was
5 extracted with pentane (4 x 500 mL/). Similar removal of the pentane gave a yellowish oil (65 g) with a small amount of suspended solid. Bromoform and remaining PPh₃ and OPPh₃ were removed by column chromatography (11 g portions 3 x each on 2 300 g silica gel columns,
10 eluted with 4:1 (v/v) hexane-OEt₂). Distillation gave 1-bromo-5-methoxyheptane (31.7 g, 80%) as a colorless oil: bp 45-7°C (15 mm); ¹H NMR (200 MHz, CDCl₃) δ 3.42 (t, 6.7 Hz, 2H), 3.33 (s, 3H), 3.09 (m, 1H), 1.88 (m, 2H), 1.4-1.6 (complex, 6H), 0.89 (t, 7.4 Hz, 3H); ¹³C
15 NMR (22.5 MHz, CDCl₃) δ 81.8, 56.5, 33.6, 33.2 32.3, 25.9, 24.2, 9.4.

5-Bromopentanol-1-acetate (Compound XXXII)

The procedure of United States Patent No. 2,922,788 was used. Acetyl bromide (420 g, 3.4 mole)
20 was combined with zinc (30 mesh, 3 g, 0.045 mole) and warmed to about 60°C for 30 min with constant stirring. Tetrahydropyran (275 g, 3.2 mole) was added dropwise over 2 h. The reaction was cooled periodically during the addition period to keep the temperature between 60
25 and 70°C. The temperature was raised to 90°C for 30 min, cooled, and then diluted with CH₂Cl₂ (500 mL). Ice was added (200 g) and the reaction was shaken vigorously for several minutes. The organic layer was washed (2 x 200 mL sat. NaHCO₃; 200 mL brine), dried
30 (MgSO₄), and stripped of solvent in vacuum. Fractional distillation gave a nearly colorless oil (602.2 g, 90%): bp 120-1°C (19 mm) (lit.¹²¹ 109-11°C (14 mm)); IR (film) cm⁻¹ 2950, 2900, 2870, 1740, 1465, 1460,

1435, 1395, 1370, 1245 (broad), 1045, 735; ^1H NMR (200 MHz, CDCl_3) δ 4.08 (t, 6.3 Hz, 2H), 3.42 (t, 6.7 Hz, 2H), 2.06 (s, 3H), 1.09 (pentet, 7 Hz, 2H), 1.4-1.77 (m, 4H); ^{13}C NMR (22.5 MHz, CDCl_3) δ 170.9, 64.0, 33.4, 32.3, 27.8, 24.6, 20.9; mass spectrum (70 eV) m/e 210, 208 (M^+ , not observed), 150, 148 ($\text{M}^+ - \text{HOAc}$, 14.5, 14.9), 73 (8.0) 69 (66.0), 68 (13.9), 67 (6.1), 61 (23.6), 55 (9.6), 43 (100.0); high resolution mass spectrum (70 eV) m/e 149.9868, 147.9888 (calculated 149.9868, 147.9888 for $\text{C}_5\text{H}_9\text{Br}$).

5-Bromo-1-pentanol (Compound XXXI)

5-Bromopentanol-1-acetate (Compound XXXII) was hydrolyzed as described for the chloride. Fractional distillation of the crude product gave 5-bromo-1-pentanol (Compound XXXI) as a colorless oil (84%): bp 60-70°C (0.4 mm) (lit. Meyers et al. Tetrahedron 27, 5979-85 (1971) 62°C (0.5 mm)); IR (film) cm^{-1} 3340 (broad), 2940, 2875, 1460, 1440, 1380, 1275, 1250, 1230, 1205, 1140, 1060, 1020, 990, 955, 890, 740, 645; ^1H NMR (200 MHz, CDCl_3) δ 3.68 (t, 6.2 Hz, 2H), 3.43 (t, 6.8 Hz, 2H), 2.38 (s, 1H), 1.90 (pentet, 7 Hz, 2H), 1.57 (m, 4H); ^{13}C NMR (22.5 MHz, CDCl_3) δ 62.3, 33.8, 32.5, 31.5, 24.5; mass spectrum (70 eV) m/e (% base) 168, 166 (M^+ , not observed), 150, 148 ($\text{M}^+ - \text{H}_2\text{O}$, 1.6, 1.6), 137, 135 ($\text{M}^+ - \text{CH}_2\text{OH}$, 7.8, 8.0), 82 (5.2), 80 (5.2), 69 (100.0), 68 (14.4), 67 (5.9), 57 (13.0), 56 (13.0), 55 (30.1); high resolution mass spectrum (70 eV) m/e 136.9783, 134.9809 (calculated 136.9789, 134.9809 for $\text{C}_4\text{H}_8\text{Br}$).

5-Chloro-1-pentanol

The procedure reported by Meyers et al. Tetrahedron 27, 5979-85 was used. 5-Chloropentanol-1-acetate (33.9 g, 0.21 mole) was combined with EtOH

(95%, 75 mL) and aqueous NaOH (2N, 90 mL) and shook until homogeneous. The solution was allowed to stand at room temperature for several hours, and the EtOH was removed in vacuum. The residue was extracted with OEt₂ (3 x 150 mL). After the extract was dried (K₂CO₃), it was stripped of solvent in vacuum and distilled, giving 5-chloro-1-pentanol as a colorless oil (21.1 g, 84%, lit.¹¹⁹ 72%): bp 35-7°C (0.02 mm) (lit.¹¹⁹ 62°C (0.5 mm)); IR (film) cm⁻¹ 3330 (broad), 2945, 2875, 1455, 1440, 1315, 1295, 1265, 1150, 1075, 1060, 1020, 1000, 965, 900, 740, 725, 655; ¹H NMR (200 MHz, CDCl₃) δ 3.67 (m, 2H), 3.55 (t, 6.5 Hz, 2H), 1.82 (pentet, 7 Hz, 2H), 1.4-1.7 (m, 4H), 1.37 (m, 1H); ¹³C NMR (22.5 MHz, CDCl₃) δ 62.4, 45.0, 32.4, 31.9, 23.2; mass spectrum (70 eV) m/e (% base) 124, 122 (M⁺, not observed), 106, 104 (M⁺ - H₂O, 0.7, 1.3), 105 (0.5), 93 (7.1), 91 (20.5), 69 (13.7), 68 (100.0), 67 (13.6), 57 (13.4), 56 (41.4), 55 (57.0).

[(5-Chloro-1-pentyl)oxy](1,1-dimethylethyl)dimethylsilane.

A mixture of t-butyldimethylsilyl chloride (29.5 g, 0.196 mole) and 5-chloro-1-pentanol (20 g, 0.163 mole) under an inert atmosphere was treated with a solution of imidazole (27.7 g, 0.407 mole) in dry DMF (40 mL). The reaction was stirred overnight at room temperature then partitioned between water (200 mL) and OEt₂ (300 mL). The aqueous layer was extracted with more OEt₂ (2 x 100 mL), and the combined extract was dried (Na₂SO₄). The OEt₂ was removed and the residue fractionally distilled. A small fore-run was collected (bp 57°C (16 mm)) and then [(5-chloro-1-pentyl)oxy](1,1-dimethylethyl)dimethylsilane as a colorless oil (44.8 g, 97%): bp 120-5°C (17 mm),

IR (film) cm^{-1} 2960, 2940, 2900, 2865, 1475, 1465, 1390, 1365, 1290, 1260, 1110, 1055, 1030, 1010, 982, 940, 910, 840, 815, 780, 725, 660; ^1H NMR (200 MHz, CDCl_3) δ 3.62 (t, 6.1 Hz, 2H), 3.54 (t, 6.7 Hz, 2H), 1.79 (pentet, 7 Hz, 2H), 1.52 (m, 4H), 0.89 (s, 9H), 0.05 (s, 6H); ^{13}C NMR (22.5 MHz, CDCl_3) δ 62.8, 44.9, 32.5, 32.1, 26.0 (3C), 23.3, 18.3 (tertiary), -5.3 (2C); mass spectrum (70 eV) m/e (% base) 238, 236 (M^+ , not observed), 181, 179 ($\text{M}^+ - \text{t-Bu.}$, 1.0, 2.7), 125 (10.4), 123 (28.3), 95 (9.0), 93 (20.3), 75 (10.6), 73 (10.3) 70 (7.6), 69 (100.0); high resolution mass spectrum (70 eV) m/e 181.0636, 179.0656 (calculated 181.0630, 179.0660 for $\text{C}_7\text{H}_{16}\text{OClSi}$).

exo-6-Acetoxybicyclo[3.3.0]octan-3-one (Compound XV)
15 from ethyl 3-oxotricyclo[3.3.0.0^{2,8}]octan-2-ylcarboxylate (Compound XIV). A solution of ethyl 3-oxotricyclo[3.3.0.0^{2,8}]octan-2-ylcarboxylate (Compound XIV, 9.4 g, 0.10 mole) and H_2SO_4 (0.5 mL) in HOAc (200 mL) was stirred and heated to 100°C for 4 hours. The
20 reaction was cooled, concentrated in vacuum, diluted with OEt_2 (400 mL), washed (sat. NaHCO_3 until no more CO_2 evolution; brine), dried (Na_2SO_4), and concentrated in vacuum once more. The yellow oil (13.7 g) was chromatographed (300 g silica gel; 4:1 (v/v) hexane-
25 OEt_2 , gradient to 1:1) giving four bands. The third band was distilled giving exo-6-acetoxybicyclo[3.3.0]octan-3-one (Compound XV, 10.6 g, 58%) as a colorless oil: bp 90°C (0.25 mm); IR (film) cm^{-1} 2950, 2870, 1745, 1740, 1445, 1410, 1380, 1365,
30 1250, 1190, 1155, 1025, 990, 965, 950, 905, 870, 800; ^1H NMR (200 MHz, CDCl_3) δ 4.94 (m, 1H), 1.3-3.1 (complex), 2.04 (s); ^{13}C NMR (22.5 MHz, CDCl_3) δ 218.6, 170.5, 81.8, 46.1, 44.5, 41.7, 38.0, 31.3, 29.1, 27.1;

mass spectrum (70 eV) m/e (% base) 182 (M^+ , 0.3), 122 (38.8), 96 (7.9), 95 (7.2), 94 (7.2), 93 (22.3), 83 (10.2), 81 (14.0), 80 (100.0), 79 (15.3), 78 (9.9), 55 (5.8); high resolution mass spectrum (70 eV) m/e
5 182.0951 (calculated 182.0943 for $C_{10}H_{14}O_3$), 122.0733 (M^+ - HOAc, calculated 122.0732 for $C_8H_{10}O$); TLC (OEt₂, vanillin dip) R_f = 0.47.

exo-2-Acetoxy Spiro[bicyclo[3.3.0]octan-7,2'[1,3]dioxolane] (Compound XVI)

10 A solution of 6-acetoxyspiro[bicyclo[3.3.0]octan-3-one Compound XV, 10.0 g, 0.055 mole), ethylene glycol (50 mL), and p-toluenesulfonic acid (a few mg) in benzene (500 mL) was heated to reflux under a Dean-Stark trap until 1 equivalent of water was removed. After cooling
15 to room temperature, the reaction was diluted with OEt₂, washed (sat. NaHCO₃; brine), dried (Na₂SO₄), and stripped of solvent in vacuum leaving a colorless oil (12.2 g, 98%), sufficiently pure for subsequent
20 reactions. IR (film) cm^{-1} 2965, 2880, 1740, 1460, 1440, 1380, 1365, 1340, 1250, 1210, 1125, 1105, 1025, 1000, 985, 950, 910, 870, 810, 735; ¹H NMR (200 MHz, CDCl₃) δ 4.91 (m, 1H), 3.91 (s, 4H), 2.70 (m, 1H), 2.49 (rough quartet, 1H), 1.4-2.15 (complex), 2.02 (s, 3H);
25 ¹³C NMR (22.5 MHz, CDCl₃) δ 170.6, 118.0, 81.9, 64.7, 64.0, 47.0, 41.5, 39.3, 38.7, 30.7, 30.3, 21.3; mass spectrum (70 eV) m/e (% base) 226 (M^+ , not observed), 167 (M^+ - OAc, 40.4), 166 (M^+ - HOAc, 100.0), 139 (10.8), 125 (45.2), 112 (13.1), 99 (26.5), 87 (9.9), 86 (26.7), 81 (13.1), 80 (10.8), 79 (15.2), 55 (20.7);
30 high resolution mass spectrum (70 eV) m/e 166.0994 (calculated 166.0994 for $C_{10}H_{14}O_2$); TLC (OEt₂, vanillin dip) R_f = 0.50.

exo-2-Hydroxy Spiro[bicyclo[3.3.0]octan-7,2'-

[1,3]dioxolane] (Compound XVII).

exo-2-Acetoxyspiro[bicyclo[3.3.0]octan-7.2'-
[1,3]dioxolane] (Compound XVI, 11.8 g, 0.052 mole) was
stirred with ethanolic KOH (156 mL of 1N KOH in 95%
5 EtOH, 0.156 mole) at room temperature for 1/2 hour.
The reaction was poured into water (500 mL) and
extracted with OEt₂ (6 x). The extract was dried
(Na₂SO₄) and concentrated in vacuum to leave the title
compound (Compound XVII, 8.52 g, 89%) as a white solid,
10 sufficiently pure for subsequent reactions. Mp 54-
5.5°C; IR (KBr) cm⁻¹ 3270 (broad), 2950, 2875, 1460,
1450, 1435, 1350, 1330, 1310, 1240, 1205, 1180, 1120,
1100, 1040, 1000, 985, 945, 900, 870, 835, 800, 720,
650, 590, 530, 470; ¹H NMR (200 MHz, CDCl₃) δ 4.04 (m,
15 1H), 4.00 (s, 4H), 2.72 (m, 1H), 2.38 (rough quartet,
1H), 1.3-2.1 (complex, 8H); ¹³C NMR (22.5 MHz, CDCl₃) δ
118.4, 79.2, 64.6, 64.0, 49.5, 41.7, 39.4, 38.6, 33.6,
30.0; mass spectrum (70 eV) m/e (% base) 184 (M⁺,
21.6), 139 (27.6), 126 (14.0), 125 (99.6), 99 (100.0),
20 96 (14.0), 86 (40.6), 83 (21.2), 81 (16.5), 79 (13.4),
67 (10.1), 57 (13.2), 55 (38.7), 53 (12.3); high
resolution mass spectrum (70 eV) m/e 184.1097
(calculated 184.1100 for C₁₀H₁₆O₃); TLC (OEt₂, vanillin
dip) R_f = 0.25.

25 Pyridinium dichromate, PDC. PDC was prepared according
to the procedure of Corey and Schmidt, Tet. Lett. 399-
402 (1979) from CrO₃ and pyridine in water.
Spiro[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane]-2-one by
PDC oxidation (Compound XIII).

30 2-Hydroxyspiro[bicyclo[3.3.0]octan-7,2'-
[1,3]dioxolane] (Compound XVII, 0.50 g, 2.7 mmole) was
added to a solution of PDC (7.15 g, 19 mmole) in DMF
(50 mL) and stirred for 3 hours at room temperature.

The reaction was poured into water (500 mL) and extracted with OEt_2 (3 x). The extract was dried (Na_2SO_4) and concentrated in vacuum giving the title compound as a colorless oil (0.27 g, 55%): TLC (OEt_2 , vanillin dip) $R_f = 0.40$. IR (film) cm^{-1} 2960, 2895, 1745, 1440, 1340, 1305, 1275, 1210, 1115, 1025, 1010, 955, 885, 810,; ^1H NMR (200 MHz, CDCl_3) δ 3.89 (s, 4H), 2.91 (m, 1H), 2.61 (rough quartet, 1H), 2.0-2.55 (complex, 6H), 1.87 (m, 1H), 1.66 (d of d, 13.5, 6 Hz, 1H); ^{13}C NMR (22.5 MHz, CDCl_3) δ 221.6, 117.5, 64.4, 64.3, 49.2, 41.6, 38.6, 37.2, 37.0, 26.4; high resolution mass spectrum (70 eV) m/e 182.0945 (calculated 182.0943 for $\text{C}_{10}\text{H}_{14}\text{O}_3$).

3-(5-Methoxy hept-1-en-yl)-cyclohexanone (Compound I)
and 3-(5-hydroxyheptyl-1-ene)-cyclohexanone (Compound II).

The adduct of triphenyl phosphine and 1-bromo-5-methoxy heptane (9.5 g 21 m mole) in 15 ml of DMSO was added in toto to a cooled (zero degrees $^{\circ}\text{C}$) stirred solution of methyl sulfinyl methyl sodium (22 m mole in 10 ml of DMSO) under inert atmosphere. The reaction was allowed to warm to room temperature over a fifteen minute period 3-(acetyloxy) cyclohexanone (3.5 g 25 m mole) was added at once and stirred for three days at room temperature. The material was hydrolyzed with dilute hydrochloric acid, and chromatographed on a 1.5 x 50 400 mesh silica gel column. The silica had been activated at 180°C , cooled in a desiccator. The column was packed in hexane, and eluted with a gradient of Et_2O and MeOH.

IR (film) cm^{-1} 3450, 2950, 2865, 2840, 1705, 1645, 1630, 1475, 1350, 1335, 1260, 1205, 1130, 990, 930, 840 and IR (film) cm^{-1} 3425, 2940, 2860, 2820, 1720, 1660,

1650, 1465, 1455, 1370, 1270, 1220, 1195, 1140, 980, 880 for the title compounds I and II respectively.

3-(5-Methoxy-pent-1-en-yl)-cyclohexanone (Compound III) and 3-(5-Hydroxy-pent-1-en-yl)-cyclohexanone (Compound IV)

5

The adduct of triphenyl phosphine and 1-bromo-5-methoxy pentane (Compound XXX, 9.0 g 21 m mole) in 15 ml of DMSO was added in toto to a cooled (zero degrees °C) stirred solution of methyl sulfinyl methyl sodium (22 m mole in 10 ml of DMSO) under inert atmosphere. The reaction was allowed to warm to room temperature over a fifteen minute period. 3-(acetyloxy) cyclohexanone (3.5 g 25 m mole) was added at once and stirred for three days at room temperature. The material was hydrolyzed with aqueous hydro-chloric acid, and chromatographed in the manner described above for Compounds I and II, to give the title compounds.

10

15

20

IR (film) cm^{-1} 3450, 2945, 2865, 2840, 1705, 1640, 1625, 1470, 1370, 1340, 1260, 1195, 1190, 1135, 990, 925, 730, 670 and IR (film) cm^{-1} 3425, 2950, 2865, 2840, 1700, 1680, 1640, 1625, 1465, 1365, 1330, 1265, 1225, 1190, 1170, 1130, 935, 725, 655, for Compounds III and IV, respectively.

25

3-(5-Methoxy hept-1-en-yl) cyclopentanone (Compound V) and 5-hydroxy-hept-1-en-yl) cyclopentanone (Compound VI).

Magnesium metal turnings (7.2 gm, .3 moles) were added to a three-neck, round bottom flask equipped with a Friedrich condenser and kept under nitrogen gas.

30

Tetrahydrofuran (300 ml) was transferred to the flask and the contents allowed to stir. A clear, colorless solution of 1-chloro-5-methoxy-2-heptene (Compound XL, 48.1 gm, 0.3 moles) was added portionwise and refluxed.

The final third portion was added and the mixture allowed to stir for three hours. The dark yellow solution was cooled to -70 degrees C, the condenser was removed and replaced with a dry ice addition funnel. A clear solution of 3-chlorocyclopentanone (35 gm, 0.3 moles) was added over one hour. The viscous solution was poured into two liters of acidic methanol and slowly warmed to room temperature. The products are chromatographed as described above for compounds I and II and the title compounds V and VI and other products are obtained. IR (film) cm⁻¹ 3435, 2950, 2905, 2810, 1730, 1660, 1620, 1475, 1440, 1420, 1380, 1370, 1180, 1138, 920, 735, 660 and IR (film) cm⁻¹ 3440, 2940, 2835, 2800, 1740, 1660, 1620, 1450, 1375, 1360, 1195, 1155, 1100, 910, 730, 665, for Compound V and VI respectively.

3-(5-Methoxy pent-1-en-yl) cyclopentanone (Compound VII) and 3-(5-hydroxy-pent-1-en-yl) cyclopentanone (Compound VIII)

Magnesium metal turnings (7.2 gm, 0.3 moles) were added to a three-neck, round bottom flask equipped with a Friedrich condenser and kept under nitrogen gas. Tetrahydrofuran (300 ml) was transferred to the flask and the contents allowed to stir. A clear, colorless solution of 1-chloro-5-methoxy-2-pentene (Compound L, 40 gm, 0.3 moles) was added portionwise and refluxed. The final third portion was added and the mixture allowed to stir for three hours. The dark yellow solution was cooled to -70 degrees C, the condenser was removed and replaced with a dry ice addition funnel. A clear solution of 3-chlorocyclopentanone (35 gm, 0.3 moles) was added over one hour. The viscous solution was poured into two liters of acidic methanol and

slowly warmed to room temperature. The products are chromatographed in the manner described above for Compounds I and II, and the title compounds VII and VIII, and other products are obtained.

5 IR (film) cm^{-1} 3450, 2945, 2865, 2840, 1705, 1640, 1625, 1470, 1370, 1340, 1260, 1195, 1190, 1135, 990, 925, 730, 670 and 3425, 2950, 2865, 2840, 1700, 1680, 1640, 1625, 1465, 1365, 1330, 1265, 1225, 1190, 1170, 1130, 935, 725, 655, for Compounds VII and VIII, respectively.

10 5-[(1,1-Dimethylethyl)dimethylsiloxy]pent-1-ylmagnesium bromide.

A mixture of Mg turnings (0.6 g, 24 mmole), [(5-bromo-1-pentyl)oxy]-(1,1-dimethylethyl)dimethylsilane (0.5 mL), and MeMgBr (0.2 mL, 3 M) in dry OEt_2 (5 mL) was stirred and heated to reflux for 5 minutes under an inert atmosphere. A solution of [(5-bromo-10-pentyl)oxy](1,1-dimethyl-ethyl)dimethylsilane (5.62 g, 20 mmole) and MeMgBr (0.2 mL, 3 M) in dry OEt_2 (20 mL) was added dropwise at a rate to maintain a gentle, unassisted reflux. After addition was complete, the reaction was heated at reflux for 45 minutes. The solution of Grignard reagent was then cooled and used immediately in the next reaction.

25 2-[5-[(1,1-Dimethylethyl)dimethylsiloxy]pent-1-yl]-2-hydroxyspiro-[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane]

A solution of spiro-[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane]-2-one (Compound XIII, 0.50 g, 2.7 mmole) in dry OEt_2 (20 mL) was added dropwise to a -78°C, stirred solution of 5-[(1,1-dimethylethyl)dimethylsiloxy]pent-1-ylmagnesium bromide (14 mmole in 25 mL OEt_2) all under an inert atmosphere. The reaction was stirred 1/2 hour at -78°C and 1 hour

at room temperature. It was poured into sat. NaHCO_3 and extracted with OEt_2 (3 x). The extract was dried (Na_2SO_4), stripped of solvent in vacuum, and chromatographed (80 g silica gel, eluted with 4:1 (v/v) hexane- OEt_2 , gradient to 100% OEt_2) giving four bands. The first band was (1,1-dimethylethyl)dimethyl(pentyloxy)silane (2.21 g, 78% of starting bromide): identical to authentic material, TLC (OEt_2 , vanillin dip) R_f = 0.7, not visible.

The second band was the Grignard addition product, Compound LX in accordance with Formula 3, see Reaction Scheme 1, (0.77 g, 74%): IR (film) cm^{-1} 3500 (broad), 2950, 2935, 2885, 2860, 1475, 1465, 1445, 1430, 1405, 1390, 1365, 1350, 1330, 1255, 1220, 1190, 1100, 1015, 995, 945, 895, 835, 815, 775, 710, 660; ^1H NMR (200 MHz, CDCl_3) δ 3.93 (m, 4H), 3.60 (t, 6.4 Hz, 2H), 6.20 (s, 1H), 2.55 (m, 1H), 2.37 (t of d, 10, 2 Hz, 1H), 1.15-2.1 (complex, 16H), 1.90 (s, 9H), 0.04 (s, 6H); ^{13}C NMR (22.5 MHz, CDCl_3) δ 119.2, 81.6, 64.4, 64.2, 63.3, 49.3, 41.7, 41.0, 40.8, 40.5, 34.8, 32.9, 30.7, 26.5, 26.0 (3C), 24.4, (22.1), 18.4, -5.2 (2C); high resolution mass spectrum (70 eV) m/e 384.2722 (M^+ , 1.2% of base, calculated 384.2697 for $\text{C}_{21}\text{H}_{40}\text{O}_4\text{Si}$), 327.1994 ($\text{M}^+ - t\text{-Bu.}$, 98.4% of base, calculated 327.1992 for $\text{C}_{17}\text{H}_{31}\text{O}_4\text{Si}$); TLC (OEt_2 , vanillin dip) R_f = 0.53.

The third band was a by-product due to the MeMgBr initiator, 2-hydroxy-2-methylspiro[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane] (0.02 g): ^1H NMR (60 MHz, CDCl_3) δ 3.95 (s, 4H), 3.2 (s, 1H), 1.1-2.8 (complex, 10H), 1.25 (s, 3H); TLC (OEt_2 , vanillin dip) R_f = 0.29.

The fourth band was the ketone reduction product, 2-hydroxyspiro-[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane] (0.04 g): ^1H NMR (60 MHz, CDCl_3) δ 4.15

(m, 1H), 3.95 (s, 4H), 1.2-3.1 (complex, 11H); TLC (OEt₂, vanillin dip) R_f = 0.23.

Dehydration of 2-[5-[(1,1-

dimethylethyl)dimethylsiloxylpent-1-yl]-2-

5 hydroxyspiro[bicyclo[3.3.0]octan-7,2'-[1,3]dioxolane]
(Compound LX), with thionyl chloride in pyridine.

A stirred solution of 2-[5-[(1,1-

dimethylethyl)dimethylsiloxylpent-1-yl]-2-

hydroxyspiro[bicyclo[3.3.0]-octan-7,2'-[1,3]dioxolane]

10 (Compound LX 0.91 g, 2.4 mmole) in dry pyridine (40 mL) under an inert atmosphere was cooled to -10°C and treated dropwise with purified SOCl₂ (5 mL). After stirring 1/2 hour at -10°C, the reaction was cooled to -25°C, poured into ice water (250 mL water and 100 g

15 ice), and extracted with OEt₂ (4 x). The extract was dried (Na₂SO₄), stripped of solvent in vacuum, and chromatographed (80 g silica gel, eluted with 4:1 (v/v hexane-OEt₂) giving a mixture of olefins, in accordance with Formula 4 (Reaction Scheme 1) as a colorless oil

20 (0.741 g, 85%): IR (film) cm⁻¹ 3040, 2955, 2935, 2885, 2860, 1650, 1475, 1465, 1435, 1390, 1360, 1330, 1255, 1215, 1105, 1045, 1025, 1005, 945, 840, 815, 780, 715, 665; ¹H NMR (200 MHz, CDCl₃) δ 5.05-5.25 (m, <1H), 3.90 (m, 4H), 3.60 (t, 6.5 Hz, 2H), 1.1-3.1 (complex, -16H),

25 0.89 (s, 9H), 0.05 (s, 6H); ¹³C NMR (22.5 MHz, CDCl₃) complex, major peaks are found at δ 146.6, 121.4, 121.3, 120.7, 118.6, 64.7, 64.6, 64.4, 63.9, 63.7, 63.2, 62.8, 62.2, 49.2, 46.0, 43.9, 42.7, 42.0, 41.8, 41.2, 41.0, 40.8, 39.0, 38.7, 38.3, 36.3, 32.7, 32.5,

30 32.3, 32.0, 31.0, 29.5, 29.3, 28.2, 27.7, 27.4, 26.0, 25.8, 22.2, 18.4, -5.2; high resolution mass spectrum (70 eV) m/e 366.2592 (M⁺, calculated 366.2591 for C₂₁H₃₈O₃Si); TLC (OEt₂, vanillin dip) R_f = 0.65.

Deprotection of olefin mixture in accordance with Formula 4. The mixture of isomers, (0.74 g, 2.0 mmole) was treated with a 5% solution of 48% aqueous HF in CH₃CH (35 mL) for 7 minutes at room temperature. The reaction was quenched with a mixture of sat. NaHCO₃ (50mL) and water (50 mL) and then extracted with CHCl₃ (100 mL; 2 x 50 mL). The extract was dried (Na₂SO₄), concentrated in vacuum, and chromatographed (80 g silica gel, eluted with 4:1 (v/v) hexane-OEt₂, gradient to 1:4) giving 3 bands. The first band was 6-(5-hydroxypent-1-yl)bicyclo[3.3.0]oct-5-en-3-one: (64 mg, 15%): IR (film) cm⁻¹ 3400 (broad), 2930, 2860, 1748,, 1460, 1440, 1395, 1325, 1275, 1250, 1225, 1190, 1130, 1075, 1060, 1020: ¹H NMR (200 MHz, CDCl₃) δ 3.64 (rough q, 2H), 3.12 (m, 1H), 2.90 (d, 21 Hz, 1H), 2.67 (d, 21 Hz, 1H), 2.62 (d of d, 18, 8.5 Hz, 1H), 2.57 (m, 1H), 2.32 (m, 2H), 2.09 (rough t, 7 Hz, 2H), 1.88 (d of d, 18, 10.5, 1H), 1.1-1.7 (complex, 7H): ¹³C NMR (22.5 MHz, CDCl₃) δ 218.7, 136.2, 135.3, 62.8, 48.0, 47.4, 38.9, 37.6, 33.0, 32.6, 29.5, 27.7, 25.7; TLC (OEt₂, vanillin dip) R_f = 0.30. This first band material partially isomerized over 2 days of standing to the 4 position olefin. ¹ NMR (200 MHz, CDCl₃) showed new peaks at δ 6.13, 6.05 and 1.1-3.3 (complex); IR (film) showed new peaks at 1700 and 1630 cm⁻¹; UV (95% EtOH) nm 292, 229 (ε_{223/9}/ε₂₉₂ = 12); TLC (OEt₂, vanillin dip) R_f = 0.32, 0.12.

Band 2 was a mixture of 3 olefins. It was mostly 6-(5-hydroxypent-1-yl)bicyclo[3.3.0]oct-6-en-3-one, and to a lesser extent the Z and E isomers of the title compound, **Compound X**, namely 6-(5-hydroxypent-1-en-yl)bicyclo[3.3.0]octan-3-one (0.275 g):

The mixture of olefins was chromatographed, as

described for compounds I and II to yield the title compound X, IR (film). 3440, 2860, 1745, 1472, 1410, 1250, 1175, 1060, 735, 660: Yield 2-3%. The IR spectrum of the title compounds IX is: 3444, 2860, 1742, 1405, 1252, 1175, 1070, 740, 665.


Compound XI and XII can be obtained by a procedure analogous to the procedure for obtaining compounds IX and X.

Compound XI IR (film) cm^{-1} . 2928, 2940, 2864, 1744, 1472, 1459, 1402, 1252, 1160, 1070, 730, 635.

Compound XII IR (film) cm^{-1} . 3428, 2944, 2858, 1738, 1765, 1468, 1409, 1245, 1165, 1065, 728, 635.


WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of compounds of the formula (i), (ii) and (iii),




10

(i)



20

(ii)



30

(iii)

where R is H, alkyl of 1 to 6 carbons, or CO-R₂ where R₂ is alkyl of 1 to 6 carbons;

R₁ is H, CH₃, or (CH₂)_m-CH₃;

n is an integer having the values of 2 to 10, and

5 m is an integer having the values of 1 to 6.

2. A compound in accordance with Claim 1 which has the formula (i).

3. A compound in accordance with Claim 2 wherein n is 3, and R₁ is H.

10 4. A compound in accordance with Claim 3 wherein R is H.

5. A compound in accordance with Claim 3 wherein R is OCH₃.

15 6. A compound in accordance with Claim 2 wherein n is 3, and R₁ is CH₂CH₃.

7. A compound in accordance with Claim 6 wherein R is H.

8. A compound in accordance with Claim 6 wherein R is OCH₃.

20 9. A compound in accordance with Claim 2 wherein R is CO-R₂.

10. A compound in accordance with Claim 1 which has the formula (ii).

25 11. A compound in accordance with Claim 10 wherein n is 3, and R₁ is H.

12. A compound in accordance with Claim 11 wherein R is H.

13. A compound in accordance with Claim 11 wherein R is OCH₃.

30 14. A compound in accordance with Claim 10 wherein n is 3, and R₁ is CH₂CH₃.

15. A compound in accordance with Claim 14 wherein R is H.

16. A compound in accordance with Claim 14 wherein R is OCH_3 .

17. A compound in accordance with Claim 10 wherein R is CO-R_2 .

5 18. A compound in accordance with Claim 1 which has the formula (iii).

19. A compound in accordance with Claim 18 wherein n is 3, and R_1 is H.

20. A compound in accordance with Claim 19 10 wherein R is H.

21. A compound in accordance with Claim 19 wherein R is OCH_3 .


22. A compound in accordance with Claim 18 wherein n is 3, and R_1 is CH_2CH_3 .

15 23. A compound in accordance with Claim 22 wherein R is H.

24. A compound in accordance with Claim 22 wherein R is OCH_3 .


25. A compound in accordance with Claim 18 20 wherein R is CO-R_2 .

26. A method of blocking androgen receptor sites in a mammal which comprises administering to said mammal a pharmaceutical composition which contains an effective dose of a compound which is selected from a 25 group consisting of compounds of the formula (i), (ii) and (iii),




(i)

54



(ii)



15

(iii)

20

where R is H, alkyl of 1 to 6 carbons, or CO-R₂ where R₂ is alkyl of 1 to 6 carbons;

R₁ is H, CH₃, or (CH₂)_m-CH₃;

n is an integer having the values of 2 to 10, and

25 m is an integer having the values of 1 to 6.

27. The method of Claim 26 wherein the pharmaceutical composition is adapted for topical administration and is applied topically.

28. The method of Claim 26 wherein the pharmaceutical composition is adapted for internal administration and is administered internally.

29. The method of Claim 26 wherein the pharmaceutical composition is administered to a mammal

afflicted with acne.

30. The method of Claim 26 wherein the pharmaceutical composition is administered to a human afflicted with male pattern baldness.

5 31. The method of Claim 26 wherein the pharmaceutical composition is administered to a mammal afflicted with keloids.

32. The method of Claim 26 wherein the pharmaceutical composition is administered to a mammal for the purpose of promoting the synthesis of elastin.

10 33. The method of Claim 26 wherein the pharmaceutical composition is administered to a human female who has a foreign body mammary insert, for the purpose of decreasing fibroblast capsules formed around the insert.

34. The method of Claim 26 wherein the pharmaceutical composition is administered topically for the purpose of treating wrinkled skin of a human.

20 35. The method of Claim 26 wherein the pharmaceutical composition is administered to a human afflicted with Alzheimer's disease.


36. The method of Claim 26 wherein the pharmaceutical composition is administered to a human afflicted with a yeast infection.

37. The method of Claim 26 wherein the pharmaceutical composition is administered to a human afflicted with osteoarthritis.

30 38. A method of controlling the growth of a microorganism or fungus which has androgen receptor sites, wherein blocking of said androgen receptor sites controls the growth of the microorganism or fungus, the


method comprising the step of administering to said microorganism or fungus a pharmaceutical composition comprising an effective dose of of a compound of the formula (i), (ii) and (iii),

5



(i)


15



20

(ii)

25



30

(iii)

where R is H, alkyl of 1 to 6 carbons, or CO-R₂ where R₂ is alkyl of 1 to 6 carbons;

R₁ is H, CH₃, or (CH₂)_m-CH₃;

n is an integer having the values of 2 to 10, and

m is an integer having the values of 1 to 6.

5

10

15

20

25

30

INTERNATIONAL SEARCH REPORT

1
national application No.
PCT/US 93/09844

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: C07C 49/743, C07C 69/145, C07C 69/24, A61K 31/12, A61K 31/22 // A01N 35/06, A01N 37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: C07C, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4689345 (W. J. KASHA ET AL), 25 August 1987 (25.08.87) --	1-38
A	US, A, 4535182 (M MINAI ET AL), 13 August 1985 (13.08.85) --	1-38
A	US, A, 5149711 (A. HAZATO ET AL), 22 Sept 1992 (22.09.92) -----	1-38

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

28 January 1994

Date of mailing of the international search report

9. 03. 94

Name and mailing address of the ISA/
European Patent Office

Authorized officer

GERD STRANDELL

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/09844

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26-38
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 26-38 relate to methods of treatment of the human or animal body by surgery or by therapy Rule 39(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/12/93

International application No.

PCT/US 93/09844

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4689345	25/08/87	AU-B- 546158	15/08/85
		AU-A- 1703383	02/12/83
		DE-A- 3378265	24/11/88
		EP-A,B- 0107733	09/05/84
		US-A- 4689349	25/08/87
		US-A- 4855322	08/08/89
		WO-A- 8304019	24/11/83
		EP-A- 0162894	04/12/85
		JP-T- 61500550	27/03/86
		WO-A- 8502177	23/05/85
US-A- 4535182	13/08/85	EP-A,B- 0102066	07/03/84
		JP-C- 1704902	27/10/92
		JP-B- 3055459	23/08/91
		JP-A- 59039852	05/03/84
		JP-C- 1722176	24/12/92
		JP-B- 4006697	06/02/92
		JP-A- 59039853	05/03/84
		JP-A- 59088443	22/05/84
US-A- 5149711	22/09/92	EP-A,B- 0332178	13/09/89
		JP-A- 1228935	12/09/89

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)